Anti‐obesity medications (AOMs) are efficacious and well tolerated in randomized controlled
trials, but findings may not be generalizable to routine clinical practice. This systematic …

Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …

Obesity has become an epidemic and a worldwide problem and its treatment is ever-
evolving. Apart from diet and exercise, medication and surgery are other options. After …

To assess the effectiveness of liraglutide 3.0 mg in post‐bariatric surgery patients, and to
determine whether this would differ based on the type of bariatric surgery. One hundred …

Aims To evaluate in a real‐world setting the effectiveness of two drugs, orlistat and
liraglutide, in patients with overweight or obesity and insufficient weight loss (WL) after a …

Background and aims Randomized clinical trials have proven the efficacy and safety of Food
and Drug Administration (FDA) approved anti-obesity medications (AOMs) for long-term use …

OBJECTIVE: The aim of this study was to investigate the clinical effectiveness of
semaglutide on weight loss, body composition and muscle strength in the Chinese …

Background As the pandemic of obesity presents an increasing serious health challenge
worldwide, additional medical interventions, especially pharmacotherapy, should be …

In the approval process for new weight management therapies, regulators typically require
estimates of effect size. Usually, as with other drug evaluations, the placebo-adjusted …

Introduction: Obesity is a global health challenge, and pharmacologic options are emerging.
Once daily subcutaneous administration of 3 mg liraglutide, a glucagon like peptide-1 …